There are 2137 resources available
330P - Comparative effectiveness of ribociclib plus fulvestrant (RIB+FUL) versus palbociclib plus letrozole (PAL+LET) as first-line (1L) treatment (Tx) of HR+/HER2− advanced breast cancer (ABC) assessed by matching-adjusted indirect comparison (MAIC)
Presenter: Peter A. Fasching
Session: E-Poster Display
Resources:
Abstract
331P - Impact of ribociclib (RIB) dose reduction on overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA (ML) -3 and -7
Presenter: Michelino De Laurentiis
Session: E-Poster Display
Resources:
Abstract
332P - Treatment-emergent (TE) neutropenia and related hospitalizations and medication discontinuations in patients (pts) with metastatic breast cancer (MBC) treated with palbociclib (PAL) or ribociclib (RIB): A real-world analysis
Presenter: Lee Schwartzberg
Session: E-Poster Display
Resources:
Abstract
333P - Ribociclib (RIB) + letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
Presenter: Paul Cottu
Session: E-Poster Display
Resources:
Abstract
334P - Lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients: Updated phase II results and dose selection
Presenter: Iurie Bulat
Session: E-Poster Display
Resources:
Abstract
335P - Resistance to CDK4/6 inhibitors: Clinical practice use of liquid biopsy to identify KRAS-mutations in ctDNA and overexpression of CDK9 in plasma derived exosomes
Presenter: Lucrezia Raimondi
Session: E-Poster Display
Resources:
Abstract
336P - PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2– BC)
Presenter: Valentina Gambardella
Session: E-Poster Display
Resources:
Abstract
337P - Efficacy of everolimus plus exemestane in CDK 4/6 inhibitors-pretreated or naïve HR-positive/HER2-negative breast cancer patients: A secondary analysis of the EVERMET study
Presenter: Federico Nichetti
Session: E-Poster Display
Resources:
Abstract
338P - Defining pathway: A novel analysis of geriatric indigenous women with breast cancer impacting survival and outcomes
Presenter: Azim Khan
Session: E-Poster Display
Resources:
Abstract
339P - Impact of blood glucose levels on the efficacy of everolimus-exemestane in patients with advanced HR-positive/HER2 negative breast cancer: The EVERMET study
Presenter: Claudio Vernieri
Session: E-Poster Display
Resources:
Abstract